Otonomy Inc (OTIC)

NASDAQ
1.750
+0.120(+7.36%)
After Hours
1.760
+0.010(+0.571%)
- Real-time Data
  • Volume:
    271,213
  • Bid/Ask:
    1.760/1.790
  • Day's Range:
    1.590 - 1.750
  • Type:Equity
  • Market:United States
  • ISIN:US68906L1052
  • CUSIP:00068906L105

OTIC Overview

Prev. Close
1.63
Day's Range
1.59-1.75
Revenue
230K
Open
1.61
52 wk Range
1.14-6.983
EPS
-0.85
Volume
271,213
Market Cap
99.19M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
383,823
P/E Ratio
-
Beta
1.97
1-Year Change
-55.7%
Shares Outstanding
56,681,315
Next Earnings Date
Nov 10, 2021
What is your sentiment on Otonomy Inc?
or
Market is currently closed. Voting is open during market hours.

Otonomy Inc News

Otonomy Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Sell
Technical IndicatorsBuyBuyBuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Otonomy Inc Company Profile

Otonomy Inc Company Profile

Employees
56

Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss.

Read More
  • any thoughts on this one ?
    0
    • the best stock that's enough?
      0
  • Nice chart
    0
    • Say again?
      0
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.